Results for the substance vorasidenib

Vorasidenib is an oral medicine used for certain brain tumours with IDH1 or IDH2 mutations. It is indicated for adults and children at least 12 years old with grade 2 astrocytoma or oligodendroglioma after surgery, including biopsy, partial resection or complete resection, when testing confirms a suitable mutation.

The medicine blocks altered IDH1 and IDH2 enzymes, which can produce substances that help tumour cells grow. The aim is to slow disease progression. It does not immediately cure the tumour and is prescribed only after oncology or neuro-oncology assessment and confirmation of the molecular profile.

Vorasidenib is usually taken once daily, at the same time each day, exactly as prescribed. Do not change the dose or take a double dose after a missed dose unless your doctor tells you to. Repeated liver blood tests are needed, especially early in treatment, because liver enzyme increases can occur.

Possible side effects include tiredness, headache, diarrhea, nausea, muscle or joint pain and seizures. Contact your doctor immediately if you notice yellow skin or eyes, dark urine, pain on the right side of the abdomen, new seizures or worsening seizures. The medicine can harm an unborn baby, so effective contraception and pregnancy advice are important.